RxDoctor Payments Data

Kevin Sponseller, MD

Family Medicine · Hartsville, SCNPI 1851709554

Payments from drug & device makers

$18,601in general payments, 2019–2025

Across 1,262 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • Boehringer Ingelheim$1K
  • Novo Nordisk$1K
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$18,41399%
  • Education$1881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)200$2,733
AstraZeneca(2 entities)88$1,474
Lilly USA, LLC139$1,458
Pfizer89$1,330
Boehringer Ingelheim91$1,268
Novo Nordisk87$1,112
GSK56$759
Takeda Pharmaceuticals U.S.A., Inc.38$615
Ironwood Pharmaceuticals, Inc37$583
Amgen(2 entities)35$555
Merck43$510
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC28$441
Bayer27$401
Otsuka America Pharmaceutical, Inc.21$390
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)19$346
Supernus Pharmaceuticals, Inc.5$317
Novartis19$309
Abbott17$275
Vanda Pharmaceuticals Inc.9$254
Corcept Therapeutics14$251
Sunovion Pharmaceuticals Inc.15$238
Teva Pharmaceuticals USA, Inc.15$207
Optinose US, Inc.10$184
Johnson & Johnson12$176
Mylan Specialty L.p.10$162
Amarin Pharma, Inc.8$137
Astellas Pharma US Inc9$133
Adlon Therapeutics L.p.8$120
Sanofi-aventis U.S. LLC8$117
Biohaven Pharmaceuticals, Inc.7$115
Xeris Pharmaceuticals, Inc.5$109
E.r. Squibb & Sons, L.L.C.8$107
Nestle Healthcare Nutrition Inc.7$104
Biohaven Pharmaceutical Holding Company Ltd.5$104
Viatris Specialty LLC4$82
Antares Pharma, Inc.4$75
Exact Sciences5$70
Eisai Inc.4$69
Forte Bio-pharma LLC2$68
Shield Therapeutics Inc4$67
Phathom Pharmaceuticals, Inc.7$66
Kowa Pharmaceuticals America, Inc.5$64
Dexcom, Inc.3$54
Jazz Pharmaceuticals Inc.3$48
Tolmar, Inc.3$42
Axsome Therapeutics, Inc.2$40
Cranial Technologies, Inc2$36
Halozyme Inc2$36
Acerus Pharmaceuticals Corporation2$34
Ardelyx, Inc.2$31
Paratek Pharmaceuticals, Inc.2$29
Shire North American Group Inc2$28
Otsuka Pharmaceutical Development & Commercialization, Inc.1$27
Sanofi1$25
Aytu Biopharma, Inc.1$24
Lundbeck LLC1$23
Vapotherm Inc1$22
3b Medical, Inc.1$22
Neos Therapeutics, LP1$17
Aimmune Therapeutics, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,601 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$216,356
Medicare patients
544
Services billed
2,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin279$401,175
MounjaroTirzepatide218$355,900
TrulicityDulaglutide96$189,498
EliquisApixaban181$179,687
OzempicSemaglutide62$111,054
JanuviaSitagliptin Phosphate66$86,722
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$74,588
OtezlaApremilast13$74,338
LinzessLinaclotide56$63,360
FarxigaDapagliflozin Propanediol43$61,949
Tresiba Flextouch U-200Insulin Degludec57$55,289
EntrestoSacubitril/Valsartan44$52,204
XareltoRivaroxaban41$42,187
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$36,898
TradjentaLinagliptin25$31,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,458$545,399314 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$1,268$442,589317 claims
PfizerEliquis, Dilantin$1,330$183,170193 claims
Novo NordiskOzempic, Rybelsus$1,112$127,78177 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,474$106,482113 claims
AmgenOtezla, Prolia$555$104,89031 claims
MerckJanuvia$510$86,72266 claims
GSKTrelegy Ellipta, Anoro Ellipta$759$83,209108 claims
AbbVieLinzess$2,733$63,36056 claims
NovartisEntresto$309$52,20444 claims
Johnson & JohnsonXarelto$176$42,18741 claims
BayerKerendia$401$19,14514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Hartsville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →